Galecto to Participate at Upcoming Investor Conferences
May 02, 2022 08:30 ET
|
Galecto, Inc.
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced...
Galecto Reports First Quarter Operating and Financial Results
April 29, 2022 08:57 ET
|
Galecto, Inc.
BOSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today...
Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF
April 26, 2022 08:30 ET
|
Galecto, Inc.
GB0139 is Galecto’s proprietary inhaled once-daily small molecule galectin-3 inhibitor GALACTIC-1 trial on track to deliver top-line results in mid-2023 BOSTON, April 26, 2022 (GLOBE NEWSWIRE)...
Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis
March 29, 2022 08:30 ET
|
Galecto, Inc.
Top-line results from GULLIVER-2 trial on track for the fourth quarter of 2022 Part 1 of GULLIVER-2 trial completed with positive results as previously announced in December 2021 BOSTON, March 29,...
Galecto Reports Financial Results for the Year Ended December 31, 2021
February 17, 2022 17:00 ET
|
Galecto, Inc.
Continued pipeline progress with three potentially first-in-class product candidates Strong cash position with cash runway into 2H 2024 BOSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc....
Galecto to Participate at Upcoming Investor Conferences
February 07, 2022 08:00 ET
|
Galecto, Inc.
BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care
January 27, 2022 07:00 ET
|
Galecto, Inc.
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease Company Provides Update on GALACTIC-1 Trial BOSTON, Jan. ...
Galecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business Officer
January 05, 2022 08:00 ET
|
Galecto, Inc.
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022
December 20, 2021 08:00 ET
|
Galecto, Inc.
Company has enrolled 10 of the targeted 16 patients in the trial Anticipates interim data in mid-2022 and topline data from full trial in 2H 2022 BOSTON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Galecto,...
Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial
December 13, 2021 08:00 ET
|
Galecto, Inc.
GB1211 observed to be safe and well tolerated in initial twelve randomized subjects, including six hepatically impaired liver cirrhosis patients Galecto initiates Part 2 of Phase 1b/2a trial in...